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Abstract
Background: Animal data have suggested that the transient receptor potential
ankyrin-1 (TRPA1) ion channel plays a key role in promoting airway inflammation
in asthma and may mediate effects of paracetamol on asthma, yet confirmatory human
data are lacking. To study associations of TRPA1 gene variants with childhood
asthma and total IgE concentration, and interactions between TRPA1 and prenatal
paracetamol exposure on these outcomes.
Methods: Weanalysedassociationsbetween31TRPA1 singlenucleotidepolymorphisms
(SNPs) and current doctor-diagnosed asthma and total IgE concentration at 7.5 years in
the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. We
sought to confirm the most significant associations with comparable outcomes in the
Prevention and Incidence ofAsthmaandMiteAllergy (PIAMA) andGenerationRbirth
cohorts. In ALSPAC, we explored interactions with prenatal paracetamol exposure.
Results: In ALSPAC, there was strong evidence for association between six SNPs and
asthma: rs959974 and rs1384001 (per-allele odds ratio for both: 1.30 (95% CI: 1.15–
1.47), p = 0.00001), rs7010969 (OR 1.28 (1.13–1.46), p = 0.00004), rs3735945 (OR
1.30 (1.09–1.55), p = 0.003), rs920829 (OR 1.30 (1.09–1.54), p = 0.004) and rs4738202
(OR 1.22 (1.07–1.39), p = 0.004). In a meta-analysis across the three cohorts, the
pooled effect estimates confirmed that all six SNPs were significantly associated with
asthma. In ALSPAC, TRPA1 associations with asthma were not modified by prenatal
paracetamol, although associations with IgE concentration were.
Conclusion: This study suggests that TRPA1 may play a role in the development of
childhood asthma. (249 words)
Introduction
The transient receptor potential ankyrin-1 (TRPA1) ion
channel is expressed on peripheral endings of primary afferent
neurons and is a highly conserved sensor of noxious reactive
electrophiles; these form covalent adducts with the receptor to
activate the neurons (1). In particular, TRPA1 is a major
oxidant sensor in the airways (2), sensing exogenous airborne
Abbreviations
TRPA1, transient receptor potential ankyrin-1; ALSPAC, Avon
Longitudinal Study of Parents and Children; PIAMA, Prevention and
Incidence of Asthma and Mite Allergy; SNP, single nucleotide
polymorphism; PAF, population attributable fraction; LD, linkage
disequilibrium.
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irritants as well as endogenous by-products of oxidative stress
(3). In keeping with this function, the TRPA1 receptor is
thought to play a key role in the cough reflex (4) and in
promoting airway inflammation in asthma (3, 5). Experiments
using knockout mice and TRPA1 antagonists have shown that
TRPA1 plays a critical role in allergic and non-allergic neuro-
genic airway inflammation and hyper-reactivity (6, 7). However,
evidence implicating TRPA1 in asthma in humans is lacking.
Following our initial discovery of an association between
frequent paracetamol (acetaminophen) use and asthma in
adults (8), we and others have reported that maternal use of
paracetamol in pregnancy was associated with an increased
risk of childhood asthma, wheezing and elevated total IgE
concentration (9). Nassini et al. (10) subsequently showed in a
rodent model that systemic administration of therapeutic
doses of paracetamol led to generation of its electrophilic and
reactive metabolite in the lung which, in turn, caused
neurogenic airway inflammation through activation of
TRPA1; they proposed that this mechanism might explain
the epidemiological link between paracetamol exposure and
asthma in humans.
In a population-based birth cohort, we investigated whether
TRPA1 (8q13) gene variants are associated with childhood
asthma and IgE concentration, and whether these associations
were modified by prenatal exposure to paracetamol. We also
sought to obtain confirmatory evidence for the most significant
SNP associations in the Prevention and Incidence of Asthma
and Mite allergy (PIAMA) and Generation R birth cohorts.
Methods
Avon Longitudinal Study of Parents and Children
Subjects
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a population-based birth cohort that recruited
14,541 predominantly white pregnant women resident in Avon,
UK, with expected dates of delivery 1st April 1991–31st
December 1992. Of these pregnancies, there were 14,062 live
births and 13,988 children alive at 1 year of age. The cohort has
been followed since birth with annual questionnaires and, since
age 7 years, with objective measures in research clinics. The
study protocol has been described previously (11, 12) (further
information at: http://www.alspac.bris.ac.uk). Ethics approval
was obtained from the ALSPAC Ethics and Law Committee
(IRB 00003312) and the Local Research Ethics Committees.
Outcomes
When the children were 7.5 years old, mothers were asked:
‘Has your child had any of the following in the past 12 months:
wheezing; asthma?’ Children were defined as having current
doctor-diagnosed asthma (primary outcome) if mothers
responded positively to the question ‘Has a doctor ever
actually said that your study child has asthma?’ and positively
to one or both of the questions on wheezing and asthma in the
past 12 months.
Serum total IgE concentration (kU/l) was measured by
fluoroimmunoassay using the Pharmacia UNICAP system
(Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden) at
7 years.
Prenatal paracetamol exposure
Mothers were asked at 18–20 weeks how often they had taken
paracetamol (‘not at all, sometimes, most days, every day’)
during their pregnancy. At 32 weeks, they were asked the same
question about use in the previous 3 months. Hence, we
defined use of paracetamol (Yes/No) in early (<18–20 weeks)
and late (20–32 weeks) pregnancy.
Genotyping and selection of TRPA1 SNPs
DNA samples were extracted from lymphoblastoid cell lines,
cord blood or venous blood collected at 7 years of age, with a
small number extracted from venous blood collected at 43–
61 months. A total of 9912 subjects were genotyped at 500,527
SNPs using the Illumina HumanHap550 quad genomewide
SNP genotyping platform. After applying rigorous exclusion
criteria, genotype data were available for 8365 unrelated
individuals (see Online Supplement for further details).
We identified 29 SNPs in TRPA1 (8q13) which had been
included in a genetic association study of cough (13). The
participating cohorts in that study were part of a large
European GWAS of asthma (the GABRIEL consortium)
(14). All SNPs within the gene region had been selected,
allowing capture of the majority of common haplotype
variations of the gene (13, 14). In addition, we identified 11
SNPs (four of which had already been selected) associated with
various pain phenotypes (15–17) and with menthol preference
in smokers (18). Of the 36 potential SNPs, five had not been
typed or could not be imputed, leaving 31 SNPs to be analysed.
Of these SNPs, 21 were genotyped and 10 were imputed. Where
genotyped data were missing, these were replaced by imputed
data if possible (see Online Table S1 and Supplement for
further details).
Statistical analysis of ALSPAC data
Although the GWAS data set only included individuals of
European ancestry, we excluded mother–child pairs from all
analyses if the mother’s reported ethnicity was non-white or
unknown (14.1% of the cohort) to further reduce potential
confounding by population substructure. We used logistic
regression to analyse relations of child TRPA1 genotype with
asthma, and linear regression to analyse associations with log-
transformed total IgE concentration. All analyses were carried
out using Stata (version 10.1). Univariate gene main effects
were evaluated as continuous per-allele effects and using
between genotype comparisons. We used Haploview (19) to
compute linkage disequilibrium (LD) statistics for the 31
TRPA1 SNPs of interest. The population attributable fraction
(PAF) was calculated using the formula: PAF = 1-PUF, where
PUF is the population unattributable fraction (20). We used
the Nyholt approach (21) updated by Li and Ji (22) to estimate
the effective number of independent marker loci in our data
(12.8 of 31) and the threshold required to keep type I error rate
at 5% after adjusting for multiple testing (p value=0.05/
12.8 = 0.004).
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PIAMA and Generation R (Netherlands)
The Prevention and Incidence of Asthma and Mite Allergy
(PIAMA) birth cohort is a multicentre study that selected 4146
pregnant women in the Netherlands in 1996/1997 (23, 24). The
Generation R Study is a population-based prospective cohort
study of pregnant women and their children in Rotterdam (25,
26). All children were born between April 2002 and January
2006, and currently followed until young adulthood. Current
doctor-diagnosed asthma at 8 years and at 6 years was defined
in PIAMA and Generation R, respectively (see Online
Supplement for further details).
We analysed the associations between TRPA1 (for SNPs
most significantly associated with asthma in ALSPAC) and
asthma separately in PIAMA and Generation R, and then
undertook a meta-analysis across the three cohorts, using a
fixed-effects model.
Other European asthma studies
In other European studies included in the GABRIEL study (14),
we explored associations between doctor-diagnosed asthma
‘ever’ (of childhood-onset) and the TRPA1 SNPs most signifi-
cantly associated with asthma in ALSPAC. We carried out these
subsidiary analyses using publicly available data from GAB-
RIEL and meta-analysed the data using a fixed-effects model.
Results
In ALSPAC, information on current doctor-diagnosed asthma
at age 7.5 years was obtained for 7221 children. After
excluding non-white mother–child pairs, and applying quality
criteria to imputed genotype data, TRPA1 genotype data were
available for 6901 children, generating a final sample of 5141
white children with complete data on asthma and genotype, of
whom 614 (11.9%) children had current doctor-diagnosed
asthma at age 7.5 years. A total of 53.9% and 42.3% of
children were exposed to paracetamol in utero during early and
late pregnancy, respectively. Data on total IgE concentration
and genotype were available for 3834 children.
TRPA1 genotype data are summarized in Table S1. TRPA1
genotype frequencies did not deviate from Hardy–Weinberg
equilibrium for the 31 SNPs of interest (p > 0.05). In PIAMA,
information on current doctor-diagnosed asthma at age
8 years was obtained for 3253 children, and TRPA1 genotype
data were available for 1968 children, generating a final sample
of 1877 white children with data on asthma and genotype, of
whom 89 (4.7%) had current doctor-diagnosed asthma at age
8 years. In Generation R, data on TRPA1 genotype and
current doctor-diagnosed asthma at age 6 years were available
for 2073 children, after excluding twins and restricting to
Caucasians only, based on genetic ancestry. Of these, 64
children (3.1%) had current doctor-diagnosed asthma.
Gene main effects in ALSPAC
Table 1 shows the per-allele associations between TRPA1
genotypes and asthma in ALSPAC. Of the 31 SNPs tested, 13
were associated with asthma (p < 0.05). The six SNPs (five
genotyped, one imputed) that were most significantly associ-
ated with asthma (p < 0.005) were as follows: rs959974 and
rs1384001 (per-allele odds ratio for both SNPs: 1.30 (95% CI:
1.15–1.47), p = 0.00001), rs7010969 (OR 1.28 (1.13–1.46),
p = 0.00004), rs3735945 (OR 1.30 (1.09–1.55), p = 0.003),
rs920829 (OR 1.30 (1.09–1.54), p = 0.004) and rs4738202
(OR 1.22 (1.07–1.39), p = 0.004). Adjustment for multiple
testing suggested that associations with these six SNPs (and
especially the first four) were unlikely to have arisen by chance
(adjusted p value threshold 0.004). With a more rigorous p
value threshold of 0.001, evidence against the null hypothesis
was still very strong for 3 SNPs.
Additional effect estimates using between genotype com-
parisons for these six SNPs in relation to asthma are shown in
Table 2. This shows that, for four of these SNPs, children who
were homozygous for the risk allele were approximately 70%
more likely to have asthma than children who were homozy-
gous for the non-risk allele. Of the 31 SNPs tested, only three
(rs959974, rs1384001, rs4738202) were nominally associated
with total IgE concentration (p < 0.05) (Table S2).
Table 1 Per-allele associations between child TRPA1 SNPs and
current doctor-diagnosed asthma at 7.5 years in ALSPAC
SNP Position
Doctor-diagnosed asthma at 7 years
N OR (95% CI) p value
rs12540984 72927920 5110 1.00 (0.84–1.18) 0.985
rs4738201 72930711 5140 1.16 (1.03–1.31) 0.013
rs6996723 72933632 5141 0.88 (0.75–1.04) 0.137
rs7827617 72934032 5141 1.21 (1.04–1.41) 0.013
rs959974 72935839 5141 1.30 (1.15–1.47) 0.00001
rs959976 72936145 5141 1.22 (1.05–1.42) 0.008
rs1384001 72936237 5141 1.30 (1.15–1.47) 0.00001
rs13279503 72939626 5116 1.08 (0.95–1.22) 0.222
rs4738202 72940861 5141 1.22 (1.07–1.39) 0.004
rs13280644 72948588 5141 0.82 (0.66–1.02) 0.075
rs13249568 72949209 5141 0.95 (0.83–1.09) 0.468
rs10504523 72951490 5141 0.95 (0.83–1.09) 0.484
rs1025926 72953158 5141 1.14 (1.00–1.30) 0.055
rs10504524 72955891 5141 0.95 (0.83–1.09) 0.479
rs13255063 72959535 5140 0.95 (0.83–1.09) 0.476
rs1025927 72963135 5138 0.82 (0.66–1.01) 0.067
rs1025928 72963258 5141 0.94 (0.83–1.07) 0.344
rs10504525 72965123 5141 1.06 (0.90–1.25) 0.494
rs3735942 72965973 5141 1.11 (0.98–1.26) 0.097
rs3735943 72966002 5141 0.88 (0.78–0.99) 0.040
rs10504526 72966552 5141 1.13 (1.01–1.28) 0.041
rs12548486 72971527 5138 1.11 (0.98–1.26) 0.102
rs10109581 72974329 5141 1.19 (1.05–1.36) 0.009
rs3735945 72974806 5141 1.30 (1.09–1.55) 0.003
rs920829 72977703 5136 1.30 (1.09–1.54) 0.004
rs1443952 72980652 5141 1.11 (0.98–1.25) 0.116
rs7010969 72982365 5141 1.28 (1.13–1.46) 0.00004
rs7011431 72982398 5141 1.20 (1.05–1.36) 0.008
rs4738206 72986348 5141 1.10 (0.97–1.25) 0.120
rs2278655 72987277 5038 1.01 (0.79–1.28) 0.964
rs13268757 72987638 5097 1.06 (0.89–1.25) 0.528
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Fig. S1 in the online supplement shows LD (r2) between the
31 TRPA1 SNPs; 29 of those SNPs are located in four LD
blocks. Of the six SNPs most significantly associated with
asthma, two (rs959974 and rs1384001) were in one block,
rs4738202 was in another block, and rs7010969, rs3735945 and
rs920829 were in a third block. We chose three of the most
significantly associated SNPs from different LD blocks
(rs959974, rs7010969 and rs4738202) to separately estimate
the proportion of asthma in the population attributable to
TRPA1 genotype (PAF). The PAF estimates were, respectively,
21.7% (95% CI: 9.6–32.2; p = 0.001), 29.1% (12.5–42.6;
p = 0.001) and 30.7% (7.7–47.9; p = 0.012).
Gene main effects in PIAMA and Generation R and meta-analysis
Table 2 also shows the associations between the six SNPs most
significantly associated with asthma in ALSPAC and asthma in
the PIAMA and Generation R cohorts. In PIAMA, there was
some evidence for association (p ≤ 0.05) with asthma for the
three SNPs most significantly associated with asthma in
ALSPAC, with effect estimates that were larger than those in
ALSPAC. In Generation R, none of the six SNPs were
associated with asthma. Fig. 1 shows the Forest plots for the
weighted per-allele associations of the six SNPs with asthma.
For all six SNPs, the pooled effect estimates confirmed
significant associations with asthma.
Gene main effects in other European asthma studies
Figs S2–S6 online show Forest plots for the meta-analysis of the
associations between TRPA1 and childhood-onset asthma
across GABRIEL studies, for five of the six SNPs most
significantly associated with asthma in ALSPAC (rs920829 was
not genotyped in GABRIEL; it was imputed in ALSPAC, but it
is in strong LD with rs3735945). The plots compare associations
with current doctor-diagnosed asthma in ALSPAC and PIAMA
versus associations with doctor-diagnosed asthma ‘ever’ (of
childhood-onset) across other GABRIEL studies, with three
studies which were exclusively of children separated from
remaining studies. The pooled effect estimates do not confirm
associations with asthma ‘ever’. Furthermore, there was evidence
of substantial heterogeneity in the effect estimates for the three
childhood GABRIEL studies.
Paracetamol analyses in ALSPAC
For the 13 SNPs associated with asthma (p < 0.05), we
stratified the per-allele associations by early and late
Table 2 Associations between the six most significantly associated TRPA1 SNPs in ALSPAC and current doctor-diagnosed asthma at 7–8 years
in ALSPAC and PIAMA, and current doctor-diagnosed asthma at 6 years in Generation R
SNP Alleles
ALSPAC PIAMA GENERATION R
N OR p-value N OR p-value N OR p-value
rs959974* G/G 1401 1.00 512 1.00 555 1.00
G/T 2615 1.33 (1.07–1.65) 0.009 932 1.36 (0.77–2.38) 0.28 1054 1.15 (0.61, 2.14) 0.67
T/T 1125 1.69 (1.32–2.16) 0.00001 433 1.82 (0.99–3.36) 0.053 464 1.39 (0.68, 2.82) 0.37
Per allele 1.30 (1.15–1.47) 0.00001 1.35 (1.00–1.83) 0.052 1.18 (0.83, 1.68) 0.37
rs1384001† C/C 1400 1.00 512 1.00 555 1.00
A/C 2616 1.33 (1.07–1.65) 0.009 933 1.36 (0.78–2.38) 0.28 1054 1.15 (0.61, 2.14) 0.67
A/A 1125 1.69 (1.32–2.15) 0.00001 432 1.83 (0.99–3.37) 0.053 464 1.39 (0.68, 2.82) 0.37
Per allele 1.30 (1.15–1.47) 0.00001 1.35 (1.00–1.83) 0.051 1.18 (0.83, 1.68) 0.37
rs4738202* A/A 483 1.00 150 1.00 179 1.00
A/G 2233 1.45 (1.02–2.05) 0.038 816 1.54 (0.54–4.41) 0.42 880 0.71 (0.30, 1.68) 0.44
G/G 2425 1.66 (1.18–2.34) 0.004 911 2.21 (0.79–6.20) 0.13 1,014 0.78 (0.34, 1.81) 0.57
Per allele 1.22 (1.07–1.39) 0.004 1.45 (1.01–2.09) 0.042 0.96 (0.65, 1.41) 0.83
rs7010969† A/A 827 1.00 299 1.00 324 1.00
A/C 2477 1.43 (1.09–1.89) 0.010 920 1.09 (0.56–2.10) 0.80 1005 1.08 (0.51, 2.32) 0.84
C/C 1837 1.74 (1.31–2.29) 0.00005 658 1.42 (0.73–2.77) 0.30 744 1.20 (0.55, 2.62) 0.65
Per allele 1.28 (1.13–1.46 0.00004 1.23 (0.89–1.68) 0.21 1.10 (0.76, 1.59) 0.61
rs3735945† C/C 4067 1.00 1519 1.00 1621 1.00
C/T 1005 1.38 (1.13–1.68) 0.002 338 1.15 (0.67–1.95) 0.61 428 1.40 (0.80, 2.47) 0.24
T/T 69 1.19 (0.59–2.41) 0.633 20 0.00 (0.00 to –)‡ 0.99 24 0.00 (0.00 to –)‡ 0.99
Per allele 1.30 (1.09–1.55) 0.003 1.01 (0.61–1.65) 0.98 1.21 (0.71, 2.04) 0.48
rs920829§ C/C 4066 1.00 1519 1.00 1621 1.00
C/T 1001 1.37 (1.12–1.68) 0.002 338 1.15 (0.67–1.95) 0.61 428 1.40 (0.80, 2.47) 0.24
T/T 69 1.19 (059–2.41) 0.634 20 0.00 (0.00 to –)‡ 0.99 24 0.00 (0.00 to –)‡ 0.99
Per allele 1.30 (1.09–1.54) 0.004 1.01 (0.61–1.65) 0.98 1.21 (0.71, 2.04) 0.48
*Genotyped in ALSPAC and in PIAMA, and imputed in Generation R.
†Genotyped in ALSPAC, and imputed in PIAMA and Generation R.
‡No asthma cases in minor allele homozygote group in PIAMA and Generation R.
§Imputed in ALSPAC and in PIAMA, and genotyped in Generation R.
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gestation paracetamol exposure. Associations were similar in
exposed and unexposed children for the six SNPs most
significantly associated with asthma overall (Table 3) and for
the remaining 7 SNPs (data not shown). For the three SNPs
associated with IgE concentration (p < 0.05), we similarly
stratified the per-allele associations by prenatal paracetamol
exposure (Table 4). TRPA1 was associated with IgE con-
centration amongst children who were exposed, especially in
later gestation, but not amongst non-exposed children (p-
interaction 0.02 for rs959974 and rs1384001, and 0.06 for
rs4738202).
Discussion
We found strong evidence for an association between TRPA1
polymorphisms and asthma in children at 7–8 years of age in
the population-based ALSPAC birth cohort. Of the six SNPs
most significantly associated with asthma in ALSPAC, three
showed some evidence of association (and larger effect
estimates) with a similar asthma phenotype in the PIAMA
birth cohort, whilst none of the six SNPs were associated with
asthma at 6 years in Generation R. However, both PIAMA
and Generation R were considerably smaller and had a lower
prevalence of current asthma, than ALSPAC, and hence lacked
statistical power to replicate findings individually. When we
meta-analysed across all three birth cohorts, the pooled effect
estimates confirmed associations with asthma overall. Given
the a priori selection of SNPs, the level of statistical significance
for the ‘top hits’ in the ALSPAC discovery data set, and
supportive evidence in PIAMA and following meta-analysis
across all three cohorts, we believe these results may represent a
causal influence of the TRPA1 gene on the risk of active
childhood asthma. Other genes in the vicinity of TRPA1 are
unlikely to explain our findings as there is little apparent LD
extending between TRPA1 and other nearby genes (1000
Genomes Phase 1 CEU (www.1000genomes.org)). To our
knowledge, these findings are novel and suggest that TRPA1
may play a role in the development of childhood asthma.
Whilst a recent study reported correlations between two
TRPA1 polymorphisms and asthma control in children with
asthma (27), it was underpowered and statistical evidence was
weak.
Figure 1 Forest plots showing meta-analysis of the per-allele associations between the six TRPA1 SNPs most significantly associated with
asthma in ALSPAC and current asthma in ALSPAC, PIAMA and Generation R.
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Importance of asthma phenotype
There is likely to be genetic heterogeneity of asthma pheno-
types in childhood (28), as demonstrated for adult asthma
phenotypes (29). This may partly explain why TRPA1 was not
associated with asthma in the other European studies. A
limitation of the GABRIEL asthma GWAS was that the
asthma ‘ever’ phenotype was not directly comparable to the
‘current’ asthma phenotype used in ALSPAC, PIAMA and
Generation R; a doctor diagnosis of asthma ‘ever’ is likely to
comprise many different phenotypes or endotypes which, when
analysed together, may lead to dilution of effects of genetic
variants (30). For example, in children, ‘asthma ever’ may
capture early transient childhood wheezing. We confirmed that
the effect estimates for the association between TRPA1 and
asthma were smaller in ALSPAC, and especially in PIAMA,
when we analysed ‘ever’ asthma rather than ‘current’ asthma in
these cohorts. Other possible reasons for the lack of association
Table 3 Per-allele associations between the six most significantly associated TRPA1 SNPs and current doctor-diagnosed asthma, stratified by
prenatal paracetamol exposure during early and late gestation in ALSPAC
SNP N
Paracetamol early in
pregnancy OR (95% C.I.) p-value N
Paracetamol later in
pregnancy OR (95% C.I.) p-value
rs959974
Exposed 2734 1.29 (1.10–1.50) 0.002 2118 1.26 (1.06–1.50) 0.008
Unexposed 2338 1.37 (1.12–1.66) 0.002 2889 1.31 (1.10–1.56) 0.002
p-interaction 0.639 p-interaction 0.765
rs1384001
Exposed 2734 1.29 (1.10–1.50) 0.002 2118 1.26 (1.06–1.50) 0.008
Unexposed 2338 1.37 (1.12–1.66) 0.002 2889 1.31 (1.10–1.56) 0.002
p-interaction 0.643 p-interaction 0.760
rs4738202
Exposed 2734 1.22 (1.03–1.45) 0.024 2118 1.23 (1.02–1.49) 0.031
Unexposed 2338 1.24 (1.00–1.54) 0.049 2889 1.18 (0.97–1.43) 0.090
p-interaction 0.910 p-interaction 0.753
rs7010969
Exposed 2734 1.25 (1.07–1.47) 0.006 2118 1.25 (1.05–1.50) 0.012
Unexposed 2338 1.34 (1.09–1.64) 0.005 2889 1.31 (1.09–1.57) 0.003
p-interaction 0.621 p-interaction 0.738
rs3735945
Exposed 2734 1.15 (0.91–1.44) 0.242 2118 1.31 (1.02–1.68) 0.036
Unexposed 2338 1.59 (1.20–2.09) 0.001 2889 1.24 (0.96–1.60) 0.096
p-interaction 0.076 p-interaction 0.755
rs920829
Exposed 2732 1.15 (0.91–1.44) 0.238 2114 1.30 (1.01–1.67) 0.041
Unexposed 2335 1.57 (1.19–2.08) 0.001 2888 1.24 (0.96–1.61) 0.093
p-interaction 0.086 p-interaction 0.809
Table 4 Per-allele associations between the three most significantly associated TRPA1 SNPs and total IgE concentration, stratified by prenatal
paracetamol exposure during early and late gestation in ALSPAC
SNP N
Paracetamol early in
pregnancy GMR* (95% C.I.) p-value N
Paracetamol later in
pregnancy GMR* (95% C.I.) p-value
rs959974
Exposed 2066 1.12 (1.01–1.24) 0.037 1587 1.22 (1.08–1.37) 0.001
Unexposed 1719 1.05 (0.94–1.17) 0.408 2149 1.01 (0.91–1.12) 0.849
p-interaction 0.414 p-interaction 0.017
rs1384001
Exposed 2066 1.12 (1.01–1.24) 0.037 1587 1.22 (1.08–1.37) 0.001
Unexposed 1719 1.05 (0.94–1.17) 0.402 2149 1.01 (0.91–1.12) 0.849
p-interaction 0.418 p-interaction 0.016
rs4738202
Exposed 2066 1.16 (1.03–1.29) 0.011 1587 1.21 (1.06–1.37) 0.003
Unexposed 1719 1.02 (0.91–1.15) 0.714 2149 1.03 (0.92–1.15) 0.585
p-interaction 0.145 p-interaction 0.062
*Geometric Mean Ratio.
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across the other European studies include differences in how
cases were selected, which may have contributed to hetero-
geneity of the asthma phenotype; unreliability of recall of
childhood-onset asthma amongst the adult studies in GAB-
RIEL; and variation in the prevalence of environmental
exposures that interact with the gene across different European
populations (31).
Mechanisms
Given that reactive oxygen species are thought to play an
important role in the pathogenesis of airways disease (32), and
the TRPA1 receptor is an important oxidant sensor expressed on
sensory neurons innervating the airways (2), it seems plausible
that TRPA1 may play a critical role in asthma pathogenesis.
Activation of TRPA1 can, through release of neuropeptides,
promote neurogenic airway inflammation (3, 5). Conversely, in
murine models of airway inflammation induced by allergen,
cigarette smoke and paracetamol, deletion or antagonism of
TRPA1 has been shown to reduce airway inflammation and
hyper-reactivity (6, 10, 33). However, as neurogenic inflamma-
tion has not been demonstrated in human asthma, there are two
other mechanisms to consider. First, TRPA1 may also influence
airway inflammation non-neuronally, as confirmed in animals
(34), and recent in vitro studies have shown that TRPA1 is
functionally expressed in human lung, including pulmonary
epithelial cells (34, 35), smooth muscle cells (34) and lung
fibroblasts (35). Second, a neuronal reflex mechanism may be
involved, as suggested by experiments in rodents (36).
The lack of modification of the association between TRPA1
and asthma by prenatal paracetamol exposure suggests that,
even if foetal TRPA1 is activated by exposure to the metabolite
of paracetamol (10) in utero, this mechanism is unlikely to
explain the association between prenatal paracetamol and
asthma. The apparent interaction we observed between prena-
tal paracetamol exposure and TRPA1 genotype on IgE
concentration is intriguing, but may be a chance finding and
we cannot offer a mechanistic explanation. We speculate that
other prenatal and post-natal oxidant exposures may be more
important than paracetamol as activators of TRPA1, thus
contributing to the association we have found between TRPA1
genotype and childhood asthma.
Conclusions and future work
Our findings suggest, for the first time, that TRPA1 may play a
role in the development of childhood asthma. In terms of
therapeutic implications, these data lend further support to the
proposition that TRPA1 antagonists may have promising
potential in asthma (4). It is important that our findings are
further replicated in adequately powered studies with compa-
rable asthma phenotypes, and we plan to explore interactions
between TRPA1 and other oxidant exposures such as tobacco
smoke and air pollution on childhood respiratory outcomes.
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